Thailand "threat" to USA over CL policy

16 March 2009

Thailand's Prime Minister, Abhisit Vejjajiva, has warned the USA that a downgrade of the Asian country's trade status would generate growing  public pressure for more compulsory licenses to be issued against  patent-protected drugs. The Bangkok Post reported that the Prime  Minister gave the warning to a US delegation that included Ambassador  Eric John and representatives of the US ASEAN Business Council.

The threat of trade sanctions against Thailand by the USA is the result  of a series of compulsory licenses issued against research-based  drugmakers under the World Trade Organization's agreement on  Trade-Related Aspects of Intellectual Property Rights (TRIPs;  Marketletters passim). Previous compounds that have been stripped of  patent protection include:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight